BrickBio expands antibody-drug conjugate programs

By The Science Advisory Board staff writers

November 10, 2020 -- BrickBio said it has received positive data on its first clinical novel antibody-drug conjugate candidate for treating breast cancer and gastric cancer.

In data reported by a contract research organization, BrickBio's BRKB-28 preclinical antibody was found during in vitro testing to eradicate the cancerous targets without targeting or adversely affecting healthy cells, according to the company.

BrickBio also said that it has expanded its internal programs aimed at developing biologics using the company's unnatural amino acid incorporation technology platform. The technology platform, which produces site-selective and site-specific unnatural amino acid coupled protein conjugation, allows the company to precisely control the drug to antibody ratio (DAR) within a homogenous product. These programs include antibody drug conjugates, novel bispecific antibody conjugates, and novel scaffolds.

BrickBio advances conjugation platform for therapeutic development
BrickBio has demonstrated the power of its conjugation platform process for the commercial development of biologics in-house and with pharmaceutical partners.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter